top of page

Congressional Briefing: Realizing the Promise of Gene Therapy: Protecting Patients & Innovation

On May 9, the Institute for Gene Therapy (IGT), along with the Alliance for Regenerative Medicine (ARM), held a Congressional briefing featuring patient and policy perspectives focused on the Centers for Medicare and Medicaid Services’ (CMS) recently proposed changes to the Medicaid Drug Rebate Program (MDRP).


If implemented, the changes to MDRP will have a negative impact on some of our country’s most vulnerable patients and future innovation for cell and gene therapy. Addressing these challenges is essential as we work to bring transformative gene therapies to patients and families living with unmet medical needs and to fortify an infrastructure that supports sustainable delivery of transformative gene therapies.

Speakers included:

  • Erik Paulsen, Chairman, Institute for Gene Therapies

  • Amanda Krzepicki, Policy Director, Autoimmune Association 

  • Madelyn Schloss, Gaucher Community Alliance

  • Kim Phelan, Hemophilia B Coalition

  • Erica Cischke, Vice President of Government Affairs, Alliance for Regenerative Medicine

  • John Feore, Policy Director, Institute for Gene Therapies 

Watch the discussion here:


bottom of page